Advances in biomaterials science have enabled previously undruggable targets to become druggable, offering the ability to target cancers, especially cancers with mutations of rat sarcoma (RAS) protein (e.g., Kirsten rat sarcoma viral oncogene homolog [KRAS], Harvey rat sarcoma viral oncogene homolog [HRAS], and neuroblastoma rat sarcoma viral oncogene homolog [NRAS]), with enhanced precision and efficacy. Here, KRAS is linked to cancer.